Geron Corporation
NASDAQ · GERN·Foster City, CA·Small-cap·Approved
Commercial-stage hematology company built around imetelstat (RYTELO), a first-in-class telomerase inhibitor approved in lower-risk MDS. Pipeline is anchored by the Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis, with an overall-survival readout expected to define a second indication.
Decks (2)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Geron August 2026 Corporate Presentation | Corporate overview | August 5, 2026 | 31 | Source |
| Geron Corporate Presentation February 2026 | Corporate overview | February 1, 2026 | 25 | Source |